Janux Therapeutics, Inc. Contract Liability (Deferred Revenue)
Janux Therapeutics, Inc. (JANX) had Contract Liability (Deferred Revenue) of $35.07 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Current $35.07M.
- 2026-03-31: Contract with Customer, Liability, Current $37.59M.
- 2025-12-31: Contract with Customer, Liability, Current $0.00.
- 2024-12-31: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $35.07M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $37.59M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 |
| 2024-06-30 | $94.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $972.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.71M 10-K · filed 2025-02-27 |
| 2023-09-30 | $3.65M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.34M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $4.93M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $5.41M 10-K · filed 2024-03-08 |
| 2022-09-30 | $5.91M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.37M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.65M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $5.16M 10-K · filed 2023-03-10 |
| 2021-09-30 | $5.26M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $5.07M 10-Q · filed 2021-08-10 |
| 2020-12-31 | $1.95M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |